1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > Motor Neurone Diseases – Pipeline Review, H1 2013

Motor Neurone Diseases – Pipeline Review, H1 2013

  • April 2013
  • -
  • Global Markets Direct
  • -
  • 37 pages

Motor Neurone Diseases – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Motor Neurone Diseases - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Motor Neurone Diseases, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Motor Neurone Diseases. Motor Neurone Diseases - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Motor Neurone Diseases.
- A review of the Motor Neurone Diseases products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Motor Neurone Diseases pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Motor Neurone Diseases.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Motor Neurone Diseases pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Motor Neurone Diseases - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Motor Neurone Diseases Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Motor Neurone Diseases 7
Motor Neurone Diseases Therapeutics under Development by Companies 9
Motor Neurone Diseases Therapeutics under Investigation by Universities/Institutes 10
Early Clinical Stage Products 11
Comparative Analysis 11
Discovery and Pre-Clinical Stage Products 12
Comparative Analysis 12
Motor Neurone Diseases Therapeutics - Products under Development by Companies 13
Motor Neurone Diseases Therapeutics - Products under Investigation by Universities/Institutes 14
Companies Involved in Motor Neurone Diseases Therapeutics Development 15
Oxford BioMedica plc 15
NeuroSearch A/S 16
Omeros Corporation 17
Motor Neurone Diseases - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Drug Profiles 23
MoNuDin - Drug Profile 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
NRP-2945 - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
GPR139 Antagonist - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
Umbilical Cord Blood - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
NS-11394 - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
c29 Peptide - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
Motor Neurone Diseases Therapeutics - Drug Profile Updates 31
Motor Neurone Diseases Therapeutics - Dormant Products 32
Motor Neurone Diseases - Product Development Milestones 33
Featured News and Press Releases 33
Jan 09, 2012: Baxter Submits Application For FDA Approval Of GAMMAGARD LIQUID To Treat Multifocal Motor Neuropathy 33
Dec 14, 2011: Calzada Announces New Applications For AOD9604 33
Dec 03, 2007: Avicena Announces Positive Phase II Data For A Combination Trial Involving AL-08 For The Treatment Of Amyotrophic Lateral Sclerosis (ALS) 34
Nov 17, 2006: Avicena Completes Patient Enrollment For ALS-08 Phase II Clinical Trial 35
Jul 06, 2006: Avicena Initiates Study Of Combination Therapies For Amyotrophic Lateral Sclerosis 35
Appendix 36
Methodology 36
Coverage 36
Secondary Research 36
Primary Research 36
Expert Panel Validation 36
Contact Us 37
Disclaimer 37



List of Tables

Number of Products Under Development for Motor Neurone Diseases, H1 2013 7
Products under Development for Motor Neurone Diseases - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Number of Products under Investigation by Universities/Institutes, H1 2013 10
Comparative Analysis by Early Clinical Stage Development, H1 2013 11
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 12
Products under Development by Companies, H1 2013 13
Products under Investigation by Universities/Institutes, H1 2013 14
Oxford BioMedica plc, H1 2013 15
NeuroSearch A/S, H1 2013 16
Omeros Corporation, H1 2013 17
Assessment by Monotherapy Products, H1 2013 18
Assessment by Stage and Route of Administration, H1 2013 20
Assessment by Stage and Molecule Type, H1 2013 22
Motor Neurone Diseases Therapeutics - Drug Profile Updates 31
Motor Neurone Diseases Therapeutics - Dormant Products 32



List of Figures

Number of Products under Development for Motor Neurone Diseases, H1 2013 7
Products under Development for Motor Neurone Diseases - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Products under Investigation by Universities/Institutes, H1 2013 10
Early Clinical Stage Products, H1 2013 11
Discovery and Pre-Clinical Stage Products, H1 2013 12
Assessment by Monotherapy Products, H1 2013 18
Assessment by Route of Administration, H1 2013 19
Assessment by Stage and Route of Administration, H1 2013 20
Assessment by Molecule Type, H1 2013 21
Assessment by Stage and Molecule Type, H1 2013 22

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Dystrophin (DMD) - Pipeline Review, H2 2016

Dystrophin (DMD) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Dystrophin (DMD) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Dystrophin (DMD) - Pipeline Review, H2 2016’, provides in depth analysis on Dystrophin (DMD) targeted pipeline therapeutics. ...

Huntingtin (Huntington Disease Protein or HTT) - Pipeline Review, H2 2016

Huntingtin (Huntington Disease Protein or HTT) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Huntingtin (Huntington Disease Protein or HTT) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Huntingtin (Huntington Disease Protein or HTT) - Pipeline Review, H2 2016’, provides in ...

Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Pipeline Review, H2 2016

Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Pipeline ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.